Chargement en cours...
Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort
The successes of checkpoint blockade immunotherapy (CBI) and BRAF(V600)-targeted therapy trials have generated substantial promise for revolutionizing the management of patients with advanced melanoma. However, because early clinical trials of CBIs and BRAF(V600)-targeted therapy either excluded or...
Enregistré dans:
| Publié dans: | Cancer Immunol Res |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6230261/ https://ncbi.nlm.nih.gov/pubmed/30002157 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0067 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|